Phase Ia.Agree, if they continued to the orginal top dose of...

Phase Ia.

Agree, if they continued to the orginal top dose of 16,000mg IV 1 hour dose, that would likely put peak plasma concentration above the MIC for 3 of the 6 ESKAPE pathogens. And if they were then to prove safety of repeat 16,000mg doses, they would likely have a clinically useful IV product for bacteraemia caused by those 3 ESKAPE pathogens.

Just remember to look at the plasma and urine concentrations together, and remember that peak plasma concentration is from the sample taken at the end of the IV infusion (of course). It's clear that 327 is efficently removed by the kidneys almost as quick as they can pump it in (and in the face of a pretty steep concentration gradient!).

I wonder if the company is quietly exploring new formulations to improve plasma half life, such as protein binding.

I'm happy with the UTI and urosepsis clinical strategy.